| Sep 26 |
Interim results for the six months ended June 30, 2024
|
| Sep 19 |
Biodexa Pharmaceuticals announces ADR ratio change
|
| Sep 19 |
ADR Ratio Change
|
| Sep 16 |
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
|
| Aug 30 |
Biodexa gets delisting letter from Nasdaq
|
| Aug 30 |
Receipt of Nasdaq Delisting Determination - Plans to Appeal
|
| Aug 12 |
Biodexa Pharmaceuticals files for 4.35B ordinary shares for holders
|
| Jul 23 |
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
|
| Jul 19 |
Biodexa Pharmaceuticals announces pricing of $5M registered direct offering
|
| Jul 19 |
Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
|
